Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
EyeBio logo — Developing a new generation of therapies to protect, restore...

EyeBio

Developing a new generation of therapies to protect, restore, and improve vision

Founded 2021 United Kingdom London, United Kingdom 104 employees Acquired Total: $3.13B Biotechnology

General Information

Company Name EyeBio
Founded Year 2021
Location United Kingdom London, United Kingdom +2
Founders / Decision Makers
Team member
Employees 104
Industries Biotechnology
Funding Stage Acquired
Social

Get notified when EyeBio moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About EyeBio

EyeBio, founded in 2021, is an innovative biotechnology company based in the United Kingdom, specializing in ophthalmology. The company's driving mission, encapsulated in its slogan—"Developing a new generation of therapies to protect, restore, and improve vision"—focuses on addressing the unmet needs of patients with sight-threatening eye diseases.

In a significant financial milestone, EyeBio recently secured a $3.00B acquisition investment from Merck in May 2024. This substantial investment underscores the confidence major industry players have in EyeBio's potential to revolutionize therapies in the eye care sector.

Operating within the Biotechnology industry, EyeBio is poised to leverage this funding to advance its pipeline of visionary therapies. The strategic investment by Merck also enhances EyeBio's capacity for innovation and its role as a leader in ophthalmological biotechnological advancements.

Taxonomy: ophthalmology, biopharmaceuticals, vision therapy, eye diseases, age-related macular degeneration, anti-vascular endothelial growth factor, sight restoration, eye disorder prevention, vision improvement, regenerative medicine, drug development, therapeutics, vision protection, sight-threatening conditions

Services & Products

Research and Development
Therapeutic Modalities
Clinical Trials
Patient Support Programs
Business Development and Licensing
Philanthropy and Medical Outreach

Target Customers

Patients with Retinal Diseases Healthcare Professionals Research Scientists Pharmaceutical Distributors Investors Healthcare Institutions

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Acquisition •••••• 1
Investor
01 May 2024
Series A •••••• 7
Investor Investor Investor Investor Investor
•••• •••• 		01 Nov 2023
Series A •••••• 5
Investor Investor Investor Investor
•••• •••• 		01 Feb 2022
Seed •••••• 1
Investor
01 Aug 2021

EyeBio Alternatives & Competitors

View All Alternatives
EyeBio vs
Acuity Medical International
Acuity Medical International

Empowering clearer vision and a brighter future for adults with sight challenges, one innovative sol...

Series Unknown
Health Care, Health and Wellness
Compare EyeBio vs Acuity Medical International
EyeBio vs
Centre for Eye Research Australia (CERA)
Centre for Eye Research Australia (CERA) Australia

Hope in sight.

Series Unknown
176 employees
Education, Health Care
Compare EyeBio vs Centre for Eye Research Australia (CERA)
EyeBio vs
Restore Vision
Restore Vision Japan

Creating a next vision

Series A
7 employees
Biotechnology, Health Care
Compare EyeBio vs Restore Vision
View all alternatives

FAQ About EyeBio

Developing a new generation of therapies to protect, restore, and improve vision
EyeBio was founded in 2021.
EyeBio is headquartered in London, United Kingdom.
EyeBio operates in the following industries: Biotechnology.
EyeBio has approximately 104 employees.
EyeBio has completed 4 funding rounds, raising a total of $3.13B. The latest funding stage is Acquired.
EyeBio offers: Research and Development, Therapeutic Modalities, Clinical Trials, Patient Support Programs, Business Development and Licensing, Philanthropy and Medical Outreach.
Top alternatives and competitors to EyeBio include Acuity Medical International, Centre for Eye Research Australia (CERA), Restore Vision, Mahathma Eye Hospital, Wills Eye Hospital. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
EyeBio and Acuity Medical International are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors EyeBio and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy